Enhancing Alzheimer's Treatment: The Role of KXS

Traditional Chinese Medicine: The Efficacy of Kai-Xin-San

With the accelerating aging population worldwide, diseases related to cognitive impairments such as dementia have become a growing concern for global public health (Jongsiriyanyong & Limpawattana, 2018). Alzheimer’s disease (AD), the predominant type of dementia, impacts countless people worldwide (Selkoe, 2002; Avila & Perry, 2021). It leads to deterioration of cognitive function, reduced quality of life, and loss of independence in advanced stages, posing a serious threat to the health and wellbeing of the elderly population.

Mild cognitive impairment (MCI), characterized by subtle declines in memory and thinking abilities without significant impact on daily activities, represents a critical juncture between normal aging and dementia (Chandra et al., 2019). The importance of focusing on MCI cannot be overstated, as it offers a potential window for intervention before the onset of irreversible AD, for which no curative treatments currently exist. This aligns with the traditional Chinese medicine principle of “treating the future disease,” emphasizing early intervention and prevention.

Kai-Xin-San (KXS), a traditional Chinese medicine prescription recorded in the “Bei Ji Qian Jin Yao Fang” by Sun Simiao, a Tang Dynasty physician, has garnered attention for its potential to treat forgetfulness. It is composed of four traditional Chinese botanical drugs, namely, Wolfiporia cocos (F.A. Wolf) Ryvarden and Gilb [Polyporaceae], Panax ginseng C.A.Mey [Araliaceae], Polygala tenuifolia Willd [Polygalaceae], and Acorus tatarinowii Schott [Acoraceae], which is a representative formula for benefiting the intellect and tranquilizing the mind.

Recent research has revealed its multifaceted pharmacological effects, including improvements in cognitive function and memory, along with antioxidant and anti-inflammatory capabilities, and enhancement of neurotrophic factors (Luo et al., 2020; Wang et al., 2020; Jiao et al., 2022; Su et al., 2023). The results of the mass spectrometry analysis demonstrated the presence of a total of 77 phyto ingredients, including 26 saponins, 13 triterpenoids, 20 oligosaccharides, 5 ketone compounds, and 13 other components, in the four botanical drugs of KXS. Among these bioactive natural components, 25 were derived from Polygala tenuifolia, primarily comprising oligosaccharides and ketone compounds; 28 were derived from Panax ginseng, predominantly saponins; 17 were derived from Poria cocos, primarily triterpenoid acids; and 5 were derived from Acorus tatarinowii, majorly β-as aryl ether, and other constituents (Li et al., 2022).

In the analysis, Lin et al. employed the UPLC-Q-Orbitrap-MS technique in conjunction with a local database to determine different phytochemicals from KXS. A total of 211 compounds were identified from KXS, including 60 from Panax ginseng, 40 from Poria cocos, and 111 from Polygala tenuifolia. Additionally, ginsenoside Rb1, ginsenoside Re, ginsenoside Rg1, Sibiricose A5, Sibiricose A6, 3,6′-Disinapoylsucrose, polygalaxanthone III, α-asarone, β-asarone, and Poria acid were identified in the serum of rats administered KXS (Gao & Lv, 2021).

The pathogenesis of MCI and its progression to AD involve complex mechanisms, with β-amyloid (Aβ) deposition playing a central role. It is a significant contributor to the loss of neurons and the deterioration of cognitive abilities (Hardy & Selkoe, 2002). Excessive Aβ accumulation not only forms neurotoxic senile plaques but also triggers chronic neuroinflammation, creating a detrimental feedback loop that accelerates cognitive decline (Zhang et al., 2019; Li et al., 2021). Furthermore, Aβ can activate the NOD-like receptor protein 3 (NLRP3) inflammasome and drive pyroptosis, a recently recognized form of inflammatory cell death that exacerbates neuroinflammation and potentially hastens MCI progression (Yu et al., 2021).

Preliminary studies suggest that KXS may exert its cognitive-enhancing effects in senescence-accelerated prone 8 (SAMP8) mice by modulating Aβ production and catabolism, thereby reducing Aβ deposition and ameliorating pathological changes in brain tissue. Additionally, metabolomic and pharmacological investigations indicate that KXS can improve neuroinflammation and cognitive function by regulating inflammatory mediators (Tangalos & Petersen, 2018; Sun et al., 2021; Wang et al., 2021). However, the specific signaling pathway through which KXS inhibits neuroinflammation and pyroptosis in the context of MCI remains unexplored.

This study aimed to elucidate the capacity of KXS in reducing neuroinflammation and pyroptosis in MCI and to uncover its underlying mechanism. By focusing on the neuroprotective mechanisms underlying the cognitive benefits of KXS, our goal is to offer a thorough insight into its healing possibilities for MCI, bridging traditional wisdom with modern molecular insights.

Mechanisms of Mild Cognitive Impairment and Alzheimer’s Disease

Mild cognitive impairment (MCI) often precedes the onset of Alzheimer’s disease (AD) and is characterized by noticeable memory and cognitive deficits. The mechanisms underlying MCI and AD are complex and multifactorial. A common pathological feature is the accumulation of amyloid-beta (Aβ) plaques, which disrupt neuronal communication and promote neuroinflammation.

Research indicates that the neurotoxic effects of Aβ are mediated through several pathways, including synaptic dysfunction, oxidative stress, and inflammatory responses. The NLRP3 inflammasome, an intracellular sensor for cellular stress, has been implicated in the pathogenesis of AD. Its activation leads to the release of pro-inflammatory cytokines such as IL-1β and IL-18, exacerbating neuroinflammation and neuronal damage (Zhang et al., 2019; Yu et al., 2021).

To combat these pathological features, KXS may offer a novel intervention by modulating these neuroinflammatory pathways. Findings from studies show that KXS can significantly reduce Aβ levels and inhibit the activation of microglia, thus ameliorating neuroinflammation and preserving cognitive function (Luo et al., 2020; Wang et al., 2020).

Table 1: Comparison of Mechanisms Involved in MCI and AD Progression

Neuroinflammation and Pyroptosis: Key Factors in Alzheimer’s Progression

Neuroinflammation is a hallmark of Alzheimer’s disease (AD) and is associated with the activation of microglia and the release of inflammatory cytokines. Chronic neuroinflammation results in neuronal damage and cognitive decline. Pyroptosis, a form of programmed cell death associated with inflammation, plays a significant role in neurodegenerative diseases, including AD.

Pyroptosis is mediated by the NLRP3 inflammasome, which, when activated, leads to the cleavage of pro-caspase-1 into active caspase-1. This subsequently promotes the maturation and secretion of pro-inflammatory cytokines such as IL-1β and IL-18, further exacerbating inflammatory responses and neuronal death (Li et al., 2021).

KXS has shown potential in modulating these pathways. Research indicates that KXS can downregulate the expression of NLRP3 and its downstream effectors, thereby reducing neuroinflammation and pyroptotic cell death in the hippocampus of SAMP8 mice (Wang et al., 2021).

Table 2: Key Cytokines Involved in Neuroinflammation

Behavioral and Cognitive Benefits of KXS in Alzheimer’s Patients

The administration of KXS has demonstrated significant cognitive and behavioral benefits in animal models of Alzheimer’s disease. In studies involving SAMP8 mice, KXS treatment resulted in improved performance in cognitive tests, including the Morris water maze (MWM) and novel object recognition (NOR) tests.

In the MWM test, KXS-treated mice exhibited shorter escape latencies and reduced swimming distances compared to untreated SAMP8 mice, indicating enhanced spatial learning and memory (Figure 1). Similarly, the NOR test revealed that KXS treatment improved object recognition memory, demonstrating its potential to enhance cognitive function in early-stage Alzheimer’s patients.

Table 3: Behavioral Test Results in SAMP8 Mice

Future Perspectives on Personalized Medicine in Alzheimer’s Treatment

The future of Alzheimer’s treatment may lean heavily towards personalized medicine, particularly with the advent of novel therapeutic strategies like KXS. Personalized medicine aims to tailor treatments based on individual patient characteristics, including genetic profiles, biomarkers, and specific disease mechanisms.

Integrating traditional Chinese medicine such as KXS with modern pharmacological approaches could provide synergistic effects that enhance treatment efficacy. Future research should focus on elucidating the specific molecular pathways modulated by KXS and exploring its combination with other therapeutic agents to optimize cognitive function and slow disease progression.

Moreover, advancements in drug delivery systems, such as 3D printing technology, can enhance the customization of drug formulations for Alzheimer’s treatment. This could improve patient compliance and therapeutic outcomes by enabling the production of tailored dosage forms that meet individual needs.

FAQ Section

What is Kai-Xin-San (KXS)?
KXS is a traditional Chinese medicine formula composed of four herbal ingredients that have been shown to enhance cognitive function and memory, particularly in the context of Alzheimer’s disease and mild cognitive impairment.

How does KXS work to improve cognitive function?
KXS is believed to modulate neuroinflammation and reduce amyloid-beta deposition, which are key factors in the progression of Alzheimer’s disease. It may also help increase neurotrophic factors that support neuronal health.

What are the benefits of personalized medicine in Alzheimer’s treatment?
Personalized medicine aims to tailor treatments to individual characteristics, leading to more effective therapies with fewer side effects. It allows for the customization of drug formulations and dosing based on patient-specific factors.

Are there any side effects associated with KXS?
KXS is generally considered safe, but as with any treatment, potential side effects can occur. It is important for patients to discuss any concerns with their healthcare provider.

What are the future directions for Alzheimer’s treatment?
Future directions include further research into the mechanisms of KXS, exploration of combination therapies, and the use of advanced drug delivery systems like 3D printing for personalized medication formulations.

References

1. Jongsiriyanyong, S., & Limpawattana, P. (2018). The epidemiology of Alzheimer’s disease: A review. Journal of the Medical Association of Thailand, 101(8), 1132-1143.
2. Selkoe, D. J. (2002). Alzheimer’s disease is a synaptic failure. Science, 298(5594), 789-791.
3. Avila, J., & Perry, G. (2021). Alzheimer’s disease: A new perspective on the role of amyloid beta. Nature Reviews Neuroscience, 22(2), 1-12.
4. Chandra, V., et al. (2019). Mild cognitive impairment: A clinical perspective. Journal of Geriatric Mental Health, 6(1), 4-12.
5. Luo, Y., et al. (2020). The pharmacological effects of Kai-Xin-San on Alzheimer’s disease. Journal of Ethnopharmacology, 254, 112758.
6. Wang, Z., et al. (2020). Neuroprotective effects of traditional Chinese medicine in Alzheimer’s disease: A review. Frontiers in Pharmacology, 11, 266.
7. Jiao, Y., et al. (2022). The neuroprotective effects of Kai-Xin-San in Alzheimer’s disease: Mechanisms and clinical implications. Pharmaceutics, 14(7), 1528.
8. Su, Y., et al. (2023). Anti-inflammatory effects of Kai-Xin-San in Alzheimer’s disease models. Frontiers in Pharmacology, 14, 837404.
9. Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science, 297(5580), 353-356.
10. Zhang, S., et al. (2019). Neuroinflammation in Alzheimer’s disease: A review. Frontiers in Immunology, 10, 1778.
11. Li, Z., et al. (2021). The role of neuroinflammation in the pathogenesis of Alzheimer’s disease. Frontiers in Aging Neuroscience, 13, 676941.
12. Yu, X., et al. (2021). Pyroptosis: A new player in Alzheimer’s disease. Frontiers in Molecular Neuroscience, 14, 635235.
13. Tangalos, E. C., & Petersen, R. C. (2018). Mild cognitive impairment: An overview. Cleveland Clinic Journal of Medicine, 85(12), 947-953.
14. Wang, Y., et al. (2021). Neuroprotective effects of traditional Chinese medicine on Alzheimer’s disease. Frontiers in Pharmacology, 12, 743.
15. Gao, X., & Lv, H. (2021). Pharmacological effects of Kai-Xin-San on neurodegenerative diseases: A review. Frontiers in Pharmacology, 12, 798.
16. Lin, R., et al. (2021). UPLC-Q-Orbitrap-MS analysis of herbal components in Kai-Xin-San. Molecules, 26(8), 2215.
17. Li, H., et al. (2022). Phytochemical profiling of Kai-Xin-San using UPLC-Q-Orbitrap-MS. Journal of Pharmaceutical Analysis, 12(8), 1272-1280.
18. Tolar, M., et al. (2024). Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer’s Disease. Clinical Pharmacokinetics, 63(2), 145-157.
19. Abushakra, S., et al. (2024). The single toxin origin of Alzheimer’s disease and other neurodegenerative disorders enables targeted approach to treatment and prevention. International Journal of Molecular Sciences, 25(5), 2727.
20. Hey, J. A., et al. (2025). Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer’s disease. Clinical Pharmacokinetics, 64(2), 185-195.